Investigatin The Causes Of Failed Efferocytosis In COPD-emphysema With A View To Identifying Novel Theraputic Targets
Funder
National Health and Medical Research Council
Funding Amount
$380,558.00
Summary
COPD is a leading cause of death. Smoking is the major cause of COPD and many sufferers are left with permanent damage and need ongoing treatment even after smoking cessation. Current treatments for COPD generally have limited efficacy. The project will identify the reason for the large number of dying cells and defective clearance of these cells that we have identified in the airways in COPD and study novel treatments that we hope will improve the health and well being of those with COPD.
Improving Functional Capacity In Patients With Chronic Lung Disease With High Intensity Respiratory Muscle Training
Funder
National Health and Medical Research Council
Funding Amount
$340,880.00
Summary
Patients with chronic respiratory disease have limited exercise capacity, which severely impairs their quality of life. The mechanisms responsible for this impairment may relate to their lung disease, or to the long-term effects that inactivity has on the cardiovascular and musculoskeletal systems. Pulmonary rehabilitation programs involving whole-body exercise are now widely used as an addition to standard medical therapy as a way of decreasing symptoms and optimising function. While these gene ....Patients with chronic respiratory disease have limited exercise capacity, which severely impairs their quality of life. The mechanisms responsible for this impairment may relate to their lung disease, or to the long-term effects that inactivity has on the cardiovascular and musculoskeletal systems. Pulmonary rehabilitation programs involving whole-body exercise are now widely used as an addition to standard medical therapy as a way of decreasing symptoms and optimising function. While these generalised, broad-based programs result in modest improvements in peripheral muscle function, cardiovascular function, functional exercise capacity and quality of life, it is now apparent they have little or no effect on respiratory muscle function, which is also greatly impaired in COPD. The aims of this study are to answer two longstanding questions that are fundamental to rehabilitation programs in patients with COPD (i) does a program of specific respiratory muscle training alone improve whole-body exercise capacity, dyspnoea, and-or quality of life? and (ii) does the addition of a program of specific respiratory muscle training to a standard whole-body exercise rehabilitation program result in improvemed exercise capacity, dyspnoea and-or quality of life to a greater degree than a program of whole-body exercise training alone? The study is of importance to patients with COPD by investigating the mechanisms underlying the improvement in exercise capacity following a rehabilitation program and the role of respiratory muscle training in such a program. By more accurately defining the mechanisms of exercise limitation we may be able to maximise the benefits obtained during a rehabilitation program, including improved work capacity, reduction in the degree of breathlessness and improved quality of life.Read moreRead less
Is Long Term Weekly Azithromycin Use For Bronchiectasis In Indigenous Children Associated With Antibiotic Resistance?
Funder
National Health and Medical Research Council
Funding Amount
$398,663.00
Summary
Aboriginal children living in remote areas such as central Australia experience unacceptably high rates of respiratory infection which can become chronic. A randomised controlled trial is being conducted to see if long-term azithromycin therapy reduces respiratory exacerbations in Aboriginal children with chronic lung disease. Concerns about the development of antibiotic resistance need to be addressed. This project aims to determine if such treatment is associated with antibiotic resistance.
A New Non-invasive Diagnostic Technique Based On Detection Of Exhaled Respiratory Pathogens.
Funder
National Health and Medical Research Council
Funding Amount
$179,300.00
Summary
We developed a special collection mask and showed that the breath of people with colds or flu contains a tiny amount of virus. Currently, diagnostic samples are collected by putting a tube into the airways - this is very uncomfortable. Our masks may provide a new and more comfortable way to diagnose lung infections. We want to build better masks and ways to detect viruses and bacteria to test out this method. This may create a new test that will improve diagnosis and treatment.
Surfactant Protein D As A Candidate Therapy In COPD
Funder
National Health and Medical Research Council
Funding Amount
$405,749.00
Summary
Smoking -related chronic bronchitis and emphysema, otherwise known COPD, costs the healthcare system over $800 million per year. People continue to suffer even after they have given up smoking, and the treatments available result in only modest improvements. COPD is associated with a a defect of the scavenging cells in the lung, which normally clear away dying cells, and some of the proteins ivolved in this process. We will investigate whether supplementing these proteins will help.
Local SAA Production Drives Glucocortosteriod Resistant Airway Inflammation In COPD
Funder
National Health and Medical Research Council
Funding Amount
$540,704.00
Summary
We have recently identified a blood marker termed SAA that is highly elevated during an acute attack of Chronic Obstructive Pulmonary Disease (COPD) mainly caused by chest infections. These episodes are a major cause of hospitalisation. Our previous studies suggest that by measuring blood SAA levels we can prevent a worsening of the attack with early intervention. We are now exploring the biological role of SAA and whether blocking SAA activity will benefit COPD patients.
Nasal CPAP For Very Preterm Infants At Birth: Does It Improve Outcome? A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$460,604.00
Summary
Neonatal respiratory distress syndrome (RDS) is the major cause of morbidity and mortality in preterm infants. Many of these infants need ventilatory support to keep them alive. In 1996 and 1997, 10,471 infants in Australia and New Zealand needed ventilatory support for a total of 72,544 days. This treatment is a great physical burden for the infants and an enormous emotional stress for their parents. Each day of treatment costs about A$2000 so their hospital treatment costs about $72 million a ....Neonatal respiratory distress syndrome (RDS) is the major cause of morbidity and mortality in preterm infants. Many of these infants need ventilatory support to keep them alive. In 1996 and 1997, 10,471 infants in Australia and New Zealand needed ventilatory support for a total of 72,544 days. This treatment is a great physical burden for the infants and an enormous emotional stress for their parents. Each day of treatment costs about A$2000 so their hospital treatment costs about $72 million a year. Of infants born less than 29 weeks' gestational age, about 40% of the survivors subsequently developed chronic lung disease (CLD). This condition is defined as prolonged dependence on supplementary oxygen therapy. CLD is associated with further costs and increased lung problems and readmissions to hospital in the first year of life. Thus, CLD is an expensive and time-consuming condition that has a high social cost. This project will determine whether treating these very premature babies from birth simply by applying oxygen under a low continuous positive pressure (CPAP) into their nose rather than the present treatment of placing a tube in the windpipe (known as intubation) and ventilation will reduce the incidence and severity of neonatal respiratory distress syndrome and subsequent chronic lung disease. The project will involve 600 babies from different, high quality neonatal intensive care units. Babies who are born at less than 29 weeks' gestation and who show signs of breathing at birth will be randomly allocated to be treated with either nasal CPAP or intubation and ventilation. This project will determine whether CPAP treatment at birth improves survival and reduces the severity of the RDS and subsequent CLD, or has no long term beneficial effect. If the trial is successful, this will be one of the most useful new treatments in neonatal medicine because it is simple to use, easier for the babies, and cheaper than ventilation.Read moreRead less
The Role Of Apoptosis And Macrophage Function In Chronic Obstructive Pulmonary Disease
Funder
National Health and Medical Research Council
Funding Amount
$463,400.00
Summary
Chronic obstructive pulmonary disease (COPD) is a complex, chronic disease of the lungs principally caused by cigarette smoking. COPD is very common and causes a great deal of debility and mortality in our community. COPD is also linked to an increased risk of lung cancer and carviovascular disease. It is estimated to cost Australians at least $800 million dollars per year in health related costs. Despite its importance, there is a limited understanding of how COPD develops and treatment options ....Chronic obstructive pulmonary disease (COPD) is a complex, chronic disease of the lungs principally caused by cigarette smoking. COPD is very common and causes a great deal of debility and mortality in our community. COPD is also linked to an increased risk of lung cancer and carviovascular disease. It is estimated to cost Australians at least $800 million dollars per year in health related costs. Despite its importance, there is a limited understanding of how COPD develops and treatment options are limited. We have identified large numbers of dying cells in the airways of people with COPD and we believe that these play a critical part in the cause and-or progression of the illness. This project will determine whether the increased rates of cell death are the result of the COPD process or part of the actual cause of the disease. This knowledge will enable us to address the urgent need to predict the risk of developing COPD in current and ex- smokers. Cells obtained from the lungs of healthy controls, current- ex smokers without COPD and current- ex smokers with COPD will be studied. The effects of current treatments for COPD on these cells as well as testing novel treatments will also be studied, paying particular attention to the effects on cell death. In this way we hope that new therapies will be identified to improve the health and well-being of those with COPD.Read moreRead less
Modulation Of Macrophage Function As A Therapy For Chronic Obstructive Pulmonary Disease (COPD)
Funder
National Health and Medical Research Council
Funding Amount
$435,589.00
Summary
We have established that defective clearance of dying cells by phagocytes in the airway can a) perpetuate inflammation in smokers with-without COPD and b) be improved by administration of therapies (Mannose binding lectin and Procysteine) in a mouse model. The current proposal specifically addresses the role of phagocytes in the ongoing airway damage in our COPD patients, and more thoroughly investigates the mechanisms and effects of administration of relevant new therapies (in a mouse model).
A Double-blind Randomised Controlled Multi-site Study Of Sertraline Compared With Placebo For Refractory Breathlessness
Funder
National Health and Medical Research Council
Funding Amount
$603,517.00
Summary
People with optimally treated emphysema often have breathlessness at rest or with little effort (dressing, preparing a meal). No medications are registered to reduce this breathlessness. This 3 year project will study whether a commonly used anti-depressant, sertraline, can reduce this breathlessness even if people are not depressed. Across Australia, 150 people will take part for at least 4 weeks to rate the unpleasantness of their breathlessness on sertraline or an identical sugar tablet.